Original Article | Published:

Genomics, Gene Therapy and Proteomics

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

Leukemia volume 24, pages 11601170 (2010) | Download Citation

Abstract

T lymphocytes expressing a chimeric antigen receptor (CAR) targeting the CD19 antigen (CAR.19) may be of value for the therapy of B-cell malignancies. Because the in vivo survival, expansion and anti-lymphoma activity of CAR.19+ T cells remain suboptimal even when the CAR contains a CD28 costimulatory endodomain, we generated a novel construct that also incorporates the interleukin-15 (IL-15) gene and an inducible caspase-9-based suicide gene (iC9/CAR.19/IL-15). We found that compared with CAR.19+ T cells, iC9/CAR.19/IL-15+ T cells had: (1) greater numeric expansion upon antigen stimulation (10-fold greater expansion in vitro, and 3- to 15-fold greater expansion in vivo) and reduced cell death rate (Annexin-V+/7-AAD+ cells 10±6% for iC9/CAR.19/IL-15+ T cells and 32±19% for CAR.19+ T cells); (2) reduced expression of the programmed death 1 (PD-1) receptor upon antigen stimulation (PD-1+ cells <15% for iC9/CAR.19/IL-15+ T cells versus >40% for CAR.19+ T cells); and (3) improved antitumor effects in vivo (from 4.7- to 5.4-fold reduced tumor growth). In addition, iC9/CAR.19/IL-15+ T cells were efficiently eliminated upon pharmacologic activation of the suicide gene. In summary, this strategy safely increases the anti-lymphoma/leukemia effects of CAR.19-redirected T lymphocytes and may be a useful approach for treatment of patients with B-cell malignancies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261–2271.

  2. 2.

    , , , , , et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. J Immunother 1999; 22: 473–480.

  3. 3.

    , , . The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009; 21: 215–223.

  4. 4.

    , , , , , et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30{zeta} artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood 2007; 110: 2620–2630.

  5. 5.

    , , . Fifteen years of gene therapy based on chimeric antigen receptors: ‘are we nearly there yet?’. Hum Gene Ther 2009; 20: 1229–1239.

  6. 6.

    , , , . Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720–724.

  7. 7.

    , , , , , et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637–1644.

  8. 8.

    , , , , , et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279–286.

  9. 9.

    , , , , . CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998; 4: 75–83.

  10. 10.

    , , , , , et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006; 108: 3890–3897.

  11. 11.

    , RIHDTCNYSJLJYRSESM. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I trial. Mole Ther 2010; 18: 666–668.

  12. 12.

    , , , , , et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12 (20 Pt 1): 6106–6115.

  13. 13.

    , , , , , et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264–1270.

  14. 14.

    , , , , , et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995–11004.

  15. 15.

    , , , , . Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20: 70–75.

  16. 16.

    , , , , , et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676–684.

  17. 17.

    , , , , , et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453–1464.

  18. 18.

    , , , , , et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 2009; 106: 3360–3365.

  19. 19.

    , , , , , et al. 4-1BB and CD28 Signaling plays a synergistic role in redirecting umbilical cord blood t cells against B-cell malignancies. Hum Gene Ther 2010; 21: 75–86.

  20. 20.

    , , , , , et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 2009; 183: 5563–5574.

  21. 21.

    , , , , , et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther 2007; 18: 712–725.

  22. 22.

    , , , , , . A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 2005; 12: 933–941.

  23. 23.

    , , . Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657–679.

  24. 24.

    , , . Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 2001; 14: 105–110.

  25. 25.

    , , , , , et al. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109: 5168–5177.

  26. 26.

    , , , , , et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247–4254.

  27. 27.

    , , , , , et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007; 110: 2793–2802.

  28. 28.

    , . Chimeric T-cell receptors for the targeting of cancer cells. Acta Haematol 2003; 110: 154–159.

  29. 29.

    , , , , , et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392–6402.

  30. 30.

    , , , , . Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol 2004; 6: 331–340.

  31. 31.

    , , , , , et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443: 350–354.

  32. 32.

    , . Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666–675.

  33. 33.

    , , , . Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161: 2791–2797.

  34. 34.

    , , , , , et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008; 16: 580–589.

  35. 35.

    , , , , , et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453–1464.

  36. 36.

    , , , , , et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci USA 2004; 101: 1969–1974.

  37. 37.

    , , , , , et al. Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2. Cancer Res 2004; 64: 8062–8067.

  38. 38.

    , , , , , . Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol 2005; 175: 7226–7234.

  39. 39.

    , , , , , et al. PD-1 expression in acute hepatitis C Virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006; 80: 11398–11403.

  40. 40.

    , , , . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.

  41. 41.

    , , , , . Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009; 114: 1528–1536.

  42. 42.

    , , , , , et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537–1544.

  43. 43.

    , , . PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009; 114: 1545–1552.

  44. 44.

    , , , , , et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562–567.

  45. 45.

    , , , , , et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417–2426.

  46. 46.

    , , , , . Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8: 299–308.

  47. 47.

    , , , , , et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 2346–2357.

  48. 48.

    . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263–274.

  49. 49.

    , , , , , et al. IL-15 renders conventional lymphocytes resistant to suppressive functions of regulatory T cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2009; 182: 6763–6770.

  50. 50.

    , , , , , et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006; 24: e20–e22.

  51. 51.

    , , , , . Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913–924.

Download references

Acknowledgements

This work was supported in part from Leukemia and Lymphoma Society Specialized Center of Research (SCOR; Grant no. 7018), the NIH Grants PO1CA94237, P50CA126752 and RO1CA131027, Leukemia and Lymphoma Society Translational Research grants, Doris Duke Charitable Foundation/Clinical Scientist development award and CLL Global Research Foundation.

Author contributions. VH, BS, CQ, MZ and JV performed the experiments. AM and BS performed the animal experiments. GD, BS and VH designed the research and analyzed the data. VH, BS and GD wrote the paper. HEH, CMR and MKB critically reviewed the paper. All authors approved the final version of the paper.

Author information

Affiliations

  1. Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA

    • V Hoyos
    • , B Savoldo
    • , C Quintarelli
    • , A Mahendravada
    • , M Zhang
    • , J Vera
    • , H E Heslop
    • , C M Rooney
    • , M K Brenner
    •  & G Dotti
  2. Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA

    • B Savoldo
    • , H E Heslop
    • , C M Rooney
    •  & M K Brenner
  3. Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX, USA

    • H E Heslop
    • , C M Rooney
    • , M K Brenner
    •  & G Dotti
  4. Department of Immunology, Baylor College of Medicine, Houston, TX, USA

    • C M Rooney
    •  & G Dotti
  5. Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA

    • C M Rooney

Authors

  1. Search for V Hoyos in:

  2. Search for B Savoldo in:

  3. Search for C Quintarelli in:

  4. Search for A Mahendravada in:

  5. Search for M Zhang in:

  6. Search for J Vera in:

  7. Search for H E Heslop in:

  8. Search for C M Rooney in:

  9. Search for M K Brenner in:

  10. Search for G Dotti in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to G Dotti.

Supplementary information

Powerpoint files

  1. 1.

    Supplementary Figure 1

Word documents

  1. 1.

    Supplementary Figure Legend

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/leu.2010.75

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Further reading